Soon Hyoung Hwang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Soon Hyoung Hwang has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Jun-Ho Jeong
Korea Institute of Machinery and Materials
2 shared publications - Sohee Jeon
Nano Lithography and Manufacturing Research Center, Korea Institute of Machinery and Materials (KIMM), Daejeon 34103, Republic of Korea
2 shared publications Beomsoo Chun
Department of Electrical and Computer Engineering Inter‐University Semiconductor Research Center, Seoul National University Seoul Republic of Korea
1 shared publicationByounghyun Jeon
Nano Lithography and Manufacturing Research Center Korea Institute of Machinery and Materials (KIMM) Daejeon Republic of Korea
1 shared publication- Byung-Ho Kang
Nano Lithography and Manufacturing Research Center, Korea Institute of Machinery and Materials (KIMM), Daejeon 34103, Republic of Korea
1 shared publication - Chang Yeol Lee
Bionanotechnology Research Center Korea Research Institute of Bioscience and Biotechnology (KRIBB) Daejeon Republic of Korea
1 shared publication
Latest Publications
- Open Access
Reconfigurable Nanogap SERS for Multiscale Molecular Sensing on Curved Surfaces
Surface‐enhanced Raman scattering (SERS) offers ultrasensitive molecular fingerprinting, yet most current substrates rely on static architectures with fixed nanostructures, which undermines their quantitative reliability and prevents conformal sensing. Here, we introduce a reconfigurable and conformable SERS platform based on Au‐coated shape memory polymer (SMP) nanopillar arrays that reversibly switch out‐of‐plane (vertical) Au─Au nanogaps. The substrate comprises Au‐coated SMP nanopillars embedded with silver nanoparticles (AgNPs) that serve as photothermal triggers and mechanical reinforcements. Compression and laser‐induced recovery of the nanopillars reversibly modulate the vertical Au─Au nanogaps from wide to narrow states, thereby tuning near‐field coupling, hotspot density, and molecular accessibility. This reversible out‐of‐plane reconfiguration enables the same platform to support detection of analytes across different size scales. The size‐adaptive sensing capability is demonstrated by the detection of a macromolecule (hemoglobin, 64 kDa) on curved stainless‐steel surfaces in the wide‐gap state and of a small molecule (thiram, 0.24 kDa) on fruit surfaces in the narrow‐gap state. The platform also maintains performance over repeated compression‐recovery and washing‐measurement cycles, confirming reusability and operational stability. Overall, this adaptive nanogap‐switching strategy offers a practical route toward reusable, size‐adaptive SERS platforms for next‐generation food safety and forensic chemical analysis.
Open AccessReconfigurable Nanogap SERS for Multiscale Molecular Sensing on Curved Surfaces
Surface‐enhanced Raman scattering (SERS) offers ultrasensitive molecular fingerprinting, yet most current substrates rely on static architectures with fixed nanostructures, which undermines their quantitative reliability and prevents conformal sensing. Here, we introduce a reconfigurable and conformable SERS platform based on Au‐coated shape memory polymer (SMP) nanopillar arrays that reversibly switch out‐of‐plane (vertical) Au─Au nanogaps. The substrate comprises Au‐coated SMP nanopillars embedded with silver nanoparticles (AgNPs) that serve as photothermal triggers and mechanical reinforcements. Compression and laser‐induced recovery of the nanopillars reversibly modulate the vertical Au─Au nanogaps from wide to narrow states, thereby tuning near‐field coupling, hotspot density, and molecular accessibility. This reversible out‐of‐plane reconfiguration enables the same platform to support detection of analytes across different size scales. The size‐adaptive sensing capability is demonstrated by the detection of a macromolecule (hemoglobin, 64 kDa) on curved stainless‐steel surfaces in the wide‐gap state and of a small molecule (thiram, 0.24 kDa) on fruit surfaces in the narrow‐gap state. The platform also maintains performance over repeated compression‐recovery and washing‐measurement cycles, confirming reusability and operational stability. Overall, this adaptive nanogap‐switching strategy offers a practical route toward reusable, size‐adaptive SERS platforms for next‐generation food safety and forensic chemical analysis.
- Open Access
Antibody-Integrated Solid-to-Gel Microfilm for Protection Against Botulinum Neurotoxin Type A
Antibodies are indispensable for protection against biological toxins and pathogens, yet their conventional liquid formulations impose severe constraints, including dosing inaccuracy caused by residual fluid remaining in the syringe and limited user convenience such as pain caused by fluid-induced tissue distension and nerve stimulation as well as instability in ambient temperature, and the requirement for low-temperature storage and logistics. These limitations critically impair rapid deployment during golden hour following acute exposure. Here, we report an antibody-integrated solid-to-gel microfilm—demonstrated with a 100 µg anti-BoNT/A dose—jet-printed and low-temperature dried directly onto metal needles for consistent, on-demand use. Upon intradermal insertion, the microfilm fully dissolves within 5 min, driven by hydration-induced swelling of a hyaluronic acid (HA) support layer and rapid release of the antibody. Time-resolved microscopy and UV–vis analysis showed a decrease in residual solid from 2.34 mm3 to 0 over 300 s, with a concomitant rise at 187 nm indicative of complete dissolution. The solid formulation maintained ambient-temperature stability for 3–6 months with pharmacokinetics comparable to conventional subcutaneous liquid injections. In a lethal BoNT/A challenge, treated mice achieved 100% survival for 12 days, whereas controls succumbed within 16 h.
Open AccessAntibody-Integrated Solid-to-Gel Microfilm for Protection Against Botulinum Neurotoxin Type A
Antibodies are indispensable for protection against biological toxins and pathogens, yet their conventional liquid formulations impose severe constraints, including dosing inaccuracy caused by residual fluid remaining in the syringe and limited user convenience such as pain caused by fluid-induced tissue distension and nerve stimulation as well as instability in ambient temperature, and the requirement for low-temperature storage and logistics. These limitations critically impair rapid deployment during golden hour following acute exposure. Here, we report an antibody-integrated solid-to-gel microfilm—demonstrated with a 100 µg anti-BoNT/A dose—jet-printed and low-temperature dried directly onto metal needles for consistent, on-demand use. Upon intradermal insertion, the microfilm fully dissolves within 5 min, driven by hydration-induced swelling of a hyaluronic acid (HA) support layer and rapid release of the antibody. Time-resolved microscopy and UV–vis analysis showed a decrease in residual solid from 2.34 mm3 to 0 over 300 s, with a concomitant rise at 187 nm indicative of complete dissolution. The solid formulation maintained ambient-temperature stability for 3–6 months with pharmacokinetics comparable to conventional subcutaneous liquid injections. In a lethal BoNT/A challenge, treated mice achieved 100% survival for 12 days, whereas controls succumbed within 16 h.
- Open Access
- 10 October 2020
- Published by MDPI AG in Pharmaceutics
- Vol. 12 (10) , 954
Effective Dispensing Methods for Loading Drugs Only to the Tip of DNA Microneedles
Here, we propose a novel and simple method to efficiently capture the diffusion of fluorescein isothiocyanate (FITC)-dextran from a biocompatible substance and load the drug only to the tip of DNA microneedles. A dispensing and suction method was chosen to fabricate the designed microneedles with efficient amounts of FITC as the drug model. Importantly, the vacuum process, which could influence the capturing of FITC diffusion from the tip, was evaluated during the manufacturing process. In addition, the simulations were consistent with the experimental results and showed apparent diffusion. Moreover, dextrans of different molecular weights labeled with FITC were chosen to fabricate the tip of microneedles for demonstrating their applicability. Finally, a micro-jetting system with a micro-nozzle (diameter: 80 μm) was developed to achieve the accurate and rapid loading of small amounts of FITC using the anti-diffusion and micro-jetting methods. Our method not only uses a simple and fast manufacturing process, but also fabricates the tips of microneedles more efficiently with FITC compared with the existing methods. We believe that the proposed method is essential for the clinical applications of the microneedle drug delivery platform.
- 10 October 2020
- Published by MDPI AG in Pharmaceutics
- Vol. 12 (10) , 954
Open AccessEffective Dispensing Methods for Loading Drugs Only to the Tip of DNA Microneedles
Here, we propose a novel and simple method to efficiently capture the diffusion of fluorescein isothiocyanate (FITC)-dextran from a biocompatible substance and load the drug only to the tip of DNA microneedles. A dispensing and suction method was chosen to fabricate the designed microneedles with efficient amounts of FITC as the drug model. Importantly, the vacuum process, which could influence the capturing of FITC diffusion from the tip, was evaluated during the manufacturing process. In addition, the simulations were consistent with the experimental results and showed apparent diffusion. Moreover, dextrans of different molecular weights labeled with FITC were chosen to fabricate the tip of microneedles for demonstrating their applicability. Finally, a micro-jetting system with a micro-nozzle (diameter: 80 μm) was developed to achieve the accurate and rapid loading of small amounts of FITC using the anti-diffusion and micro-jetting methods. Our method not only uses a simple and fast manufacturing process, but also fabricates the tips of microneedles more efficiently with FITC compared with the existing methods. We believe that the proposed method is essential for the clinical applications of the microneedle drug delivery platform.